BioWorld

Feb. 14, 2007

Omeros Raises $63M In Series E To Fund Broad Product Pipeline

Omeros Corp. set out to raise $20 million in its Series E financing round, but ended up bringing in more than $63 million by the time it was all over. (BioWorld Today) Read More

PDUFA Should Move Forward Unencumbered, BIO Advises

Pharmacopeia Gets $15M Up Front In Organon Deal

HGS Starts Phase III Trial With LymphoStat-B In Lupus

Cyclacel Raises $36M Through Direct Offering At Market Price

Locus Round Raises $30.2M To Push Cancer Drug, More

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 9, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Development and characterization of anti-CD19 in vivo CAR T therapy

BioWorld Science

Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...

Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome

BioWorld Science

The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...